Annals of medicine · 2026
Prognostic value of peak tricuspid regurgitation velocity in hospitalized patients with heart failure with preserved ejection fraction: an multi-institutional study.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Chieh-Yu, Chen Chun-Chi, Tsai Ming-Lung, Hsieh Ming-Jer, Lee Cheng-Hung, Chen Tien-Hsing, Chen Shao-Wei, Chang Shang-Hung, Chu Pao-Hsien, Hsieh I-Chang, Wen Ming-Shien, Chen Dong-Yi
Аннотация
OBJECTIVE: Heart failure with preserved ejection fraction (HFpEF) represents a significant clinical challenge with limited prognostic markers. The prognostic value of Doppler-derived peak tricuspid regurgitation velocity (TRVmax) in HFpEF patients remains underexplored.
METHODS: This retrospective cohort study analysed 6,438 patients with HFpEF hospitalized for acute heart failure between 2007 and 2018. Patients were stratified into three groups based on baseline TRVmax values: ≤2.8 m/s, 2.9-3.4 m/s and >3.4 m/s. The primary outcome was a composite of heart failure rehospitalization and cardiovascular mortality. Association between TRVmax levels and the risks of outcome was evaluated using Cox proportional hazards model with adjustment for established risk factors.
RESULTS: During the median follow-up of 2 years (interquartile range: 0.8-4 years), increasing incidence rates of the composite outcome were observed across the three groups (17.8, 21.2 and 23.9 per 100 person-years, respectively). Compared to the TRVmax ≤2.8 m/s group, significantly higher risks were observed in the TRVmax 2.9-3.4 m/s group (adjusted HR: 1.11, 95% CI: 1.003-1.22) and TRVmax >3.4 m/s group (adjusted HR: 1.23, 95% CI: 1.09-1.39). Each 0.5 m/s increase in TRVmax was associated with a 7% increase in composite outcome risk (HR: 1.07, 95% CI: 1.04-1.10).
CONCLUSIONS: TRVmax exceeding 2.8 m/s has prognostic value for heart failure rehospitalization and cardiovascular mortality in HFpEF patients, suggesting its potential utility as a risk stratification tool in this population.
METHODS: This retrospective cohort study analysed 6,438 patients with HFpEF hospitalized for acute heart failure between 2007 and 2018. Patients were stratified into three groups based on baseline TRVmax values: ≤2.8 m/s, 2.9-3.4 m/s and >3.4 m/s. The primary outcome was a composite of heart failure rehospitalization and cardiovascular mortality. Association between TRVmax levels and the risks of outcome was evaluated using Cox proportional hazards model with adjustment for established risk factors.
RESULTS: During the median follow-up of 2 years (interquartile range: 0.8-4 years), increasing incidence rates of the composite outcome were observed across the three groups (17.8, 21.2 and 23.9 per 100 person-years, respectively). Compared to the TRVmax ≤2.8 m/s group, significantly higher risks were observed in the TRVmax 2.9-3.4 m/s group (adjusted HR: 1.11, 95% CI: 1.003-1.22) and TRVmax >3.4 m/s group (adjusted HR: 1.23, 95% CI: 1.09-1.39). Each 0.5 m/s increase in TRVmax was associated with a 7% increase in composite outcome risk (HR: 1.07, 95% CI: 1.04-1.10).
CONCLUSIONS: TRVmax exceeding 2.8 m/s has prognostic value for heart failure rehospitalization and cardiovascular mortality in HFpEF patients, suggesting its potential utility as a risk stratification tool in this population.